1
|
Sokol MB, Yabbarov NG, Mollaeva MR, Chirkina MV, Mollaev MD, Zabolotsky AI, Kuznetsov SL, Nikolskaya ED. Alpha-fetoprotein mediated targeting of polymeric nanoparticles to treat solid tumors. Nanomedicine (Lond) 2022; 17:1217-1235. [PMID: 36136593 DOI: 10.2217/nnm-2022-0097] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Background: Serious side effects caused by paclitaxel formulation, containing toxic solubilizer Cremophor® EL, and its nonspecific accumulation greatly limit clinical paclitaxel application. Aim: To design paclitaxel-loaded copolymer of lactic and glycolic acids nanoparticles decorated with alpha-fetoprotein third domain (rAFP3d-NP) to increase paclitaxel safety profile. Methods: rAFP3d-NP was obtained via carbodiimide technique. Results: The particles were characterized with high paclitaxel loading content of 5% and size of 280 nm. rAFP3d-NP revealed biphasic profile with 67% release of paclitaxel during 220 h. Increased area under the curveinf and mean residence time values after rAFP3d-NP administration confirmed prolonged blood circulation compared with paclitaxel. rAFP3d-NP demonstrated significant tumor growth inhibition at 4T1 and SKOV-3 models. Conclusion: rAFP3d-NP is a promising delivery system for paclitaxel and can be applied similarly for delivery of other hydrophobic drugs.
Collapse
Affiliation(s)
- Mariya B Sokol
- NM Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, Moscow, 119334, Russia.,JSC Russian Research Center for Molecular Diagnostics and Therapy, Moscow, 117149, Russia
| | - Nikita G Yabbarov
- NM Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, Moscow, 119334, Russia.,JSC Russian Research Center for Molecular Diagnostics and Therapy, Moscow, 117149, Russia
| | - Mariia R Mollaeva
- NM Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, Moscow, 119334, Russia.,JSC Russian Research Center for Molecular Diagnostics and Therapy, Moscow, 117149, Russia
| | - Margarita V Chirkina
- NM Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, Moscow, 119334, Russia.,JSC Russian Research Center for Molecular Diagnostics and Therapy, Moscow, 117149, Russia
| | - Murad D Mollaev
- JSC Russian Research Center for Molecular Diagnostics and Therapy, Moscow, 117149, Russia.,Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117198, Russia
| | - Artur I Zabolotsky
- JSC Russian Research Center for Molecular Diagnostics and Therapy, Moscow, 117149, Russia.,Lomonosov Moscow State University, Biological Faculty, Department of Biochemistry, Moscow, 119991, Russia
| | | | - Elena D Nikolskaya
- NM Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, Moscow, 119334, Russia.,JSC Russian Research Center for Molecular Diagnostics and Therapy, Moscow, 117149, Russia
| |
Collapse
|
2
|
Synergetic Enhancement of Tumor Double-Targeted MRI Nano-Probe. Int J Mol Sci 2022; 23:ijms23063119. [PMID: 35328540 PMCID: PMC8955029 DOI: 10.3390/ijms23063119] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 02/25/2022] [Accepted: 03/10/2022] [Indexed: 12/10/2022] Open
Abstract
The conventional targeted delivery of chemotherapeutic and diagnostic agents utilizing nanocarriers is a promising approach for cancer theranostics. Unfortunately, this approach often faces hindered tumor access that decreases the therapeutic index and limits the further clinical translation of a developing drug. Here, we demonstrated a strategy of simultaneously double-targeting the drug to two distinct cites of tumor tissue: the tumor endothelium and cell surface receptors. We used fourth-generation polyamideamine dendrimers modified with a chelated Gd and functionalized with selectin ligand and alpha-fetoprotein receptor-binding peptide. According to the proposed strategy, IELLQAR peptide promotes the conjugate recruitment to the tumor inflammatory microenvironment and enhances extravasation through the interaction of nanodevice with P- and E-selectins expressed by endothelial cells. The second target moiety-alpha-fetoprotein receptor-binding peptide-enhances drug internalization into cancer cells and the intratumoral retention of the conjugate. The final conjugate contained 18 chelated Gd ions per dendrimer, characterized with a 32 nm size and a negative surface charge of around 18 mV. In vitro contrasting properties were comparable with commercially available Gd-chelate: r1 relaxivity was 3.39 for Magnevist and 3.11 for conjugate; r2 relaxivity was 5.12 for Magnevist and 4.81 for conjugate. By utilizing this dual targeting strategy, we demonstrated the increment of intratumoral accumulation, and a remarkable enhancement of antitumor effect, resulting in high-level synergy compared to monotargeted conjugates. In summary, the proposed strategy utilizing tumor tissue double-targeting may contribute to an enhancement in drug and diagnostic accumulation in aggressive tumors.
Collapse
|